Akero Therapeutics is a biopharmaceutical company based in South San Francisco that focuses on developing therapies for cardio-metabolic nonalcoholic steatohepatitis (NASH). The company's primary product, efruxifermin (EFX), is an analog of fibroblast growth factor 21 and aims to regulate metabolism and improve overall health. Akero is currently conducting a Phase 2a clinical trial, the BALANCED study, to test the efficacy of EFX on biopsy-confirmed NASH patients.